Auspherix gets $1m in financing
23 October, 2014 by Dylan Bushell-EmblingThe Medical Research Commercialisation Fund has granted $1m in financing to early-stage anti-infectives company Auspherix.
Anatara preps manufacturing for Detach trial
21 October, 2014 by Dylan Bushell-EmblingAnatara Lifesciences is taking steps towards registration with the AVPMA for non-antibiotic diarrhoea treatment Detach, initiating the manufacturing process for Australian trials in pigs.
ATSE elects 2014 Fellows
21 October, 2014The Australian Academy of Technological Sciences and Engineering (ATSE) has elected 25 new Fellows for 2014. The academy is an independent body of 800 eminent scientists and engineers seeking to enhance Australia's prosperity through technological innovation.
AusBiotech tells inquiry why 1.5% cut is not benign for biotech
21 October, 2014AusBiotech said in its submission to the Inquiry into the 'Tax and Superannuation Laws Amendment (2014 Measures No 5) Bill 2014' that the seemingly small but not benign change, announced in the May 2014 Federal Budget, will permanently impact companies in tax loss.
Randox aspirin-resistance test gets TGA tick
17 October, 2014 by Dylan Bushell-EmblingThe TGA has approved a Randox Laboratories test to help measure aspirin resistance in patients taking the drug to reduce heart attack risk.
Anatara Lifesciences trading on ASX
16 October, 2014 by Dylan Bushell-EmblingAnatara Lifesciences (ASX:ANR) has started trading on the ASX, after conducting a $7m IPO to raise funds to commercialise its non-antibiotic diarrhoea treatment.
AusBiotech welcomes industry agenda as a win for common sense
16 October, 2014Long-awaited restoration in the tax treatment of employee share schemes (ESS) and the announcement that Australian manufacturers of medical devices will be able to register routine medical devices using certification from European bodies were amid the changes that AusBiotech warmly welcomed when the government released its Industry Innovation and Competitiveness Agenda (IICA).
Medical research: seeking the right company
16 October, 2014 by Graeme O'NeillAustralia excels in biomedical research but sucks at commercialisation. Professor Frank Gannon says that needs to change.
CSL launches $950m share buyback
15 October, 2014 by Dylan Bushell-EmblingCSL (ASX:CSL) chairman Professor John Shine used his AGM address to announce a $950m share buyback and detail the company's achievements over the past 12 months.
Manufacturing matters to Australia
14 October, 2014With manufacturing at the forefront of public policy discourse, AusBiotech is to host the inaugural Advanced Manufacturing Summit to facilitate discussions to drive change and embrace the opportunities for Australia's current and future manufacturers and their supply chains.
Eye Co gets European patent for eye disease drug
13 October, 2014 by Dylan Bushell-EmblingMelbourne's Eye Co has picked up a European patent covering a new class of steroids to treat diabetic eye disease.
Analytica raising $4m for PeriCoach launch
10 October, 2014 by Dylan Bushell-EmblingAnalytica (ASX:ALT) has secured a CE Mark for its PeriCoach device and has launched an up to $4m capital raising to help fund marketing ahead of its formal launch in Australia.
Annual Report 2014: AusBiotech "facilitating global development"
09 October, 2014The AusBiotech Annual Report 2014 is now available, detailing how AusBiotech is delivering on its plan to facilitate global development of the Australian life sciences industry.
BVA's bionic eye implant shown to be safe
09 October, 2014 by Dylan Bushell-EmblingBionic Vision Australia's (BVA) prototype 24-channel percutaneous connector implant was found to be safe during its first clinical trial in retinosis pigmentosa.
Public forum on biotech's role in treatment of dementias and Alzheimer's
07 October, 2014With more than 332,000 Australians currently living with dementia and this figure expected to increase to 400,000 in less than a decade, AusBiotech will hold a free public forum with Australia's leading experts discussing what the future holds for the treatment and prevention of dementias and Alzheimer's and the supports available for those affected.
